Targeting Cancer
Language: English
Published by Cold Spring Harbor Laboratory Pr, 2017
- Hardcover
- New
Seller: Revaluation Books, Exeter, United KingdomRevaluation Books
AbeBooks seller since January 6, 2003
Condition: New
US$ 307.62
Quantity: 1 available
Add to basketItem description from seller
Seller Inventory # __1621822095
- Title
- Targeting Cancer
- Author
- Not Available (Not Available)
- Publisher
- Cold Spring Harbor Laboratory Pr
- Publication year
- 2017
- Condition
- Brand New
- Binding
- Hardcover
- Language
- English
- ISBN 10
- 1621822095
- ISBN 13
- 9781621822097
- Item weight
- 1.23 kilograms
science can drive improvements in diagnostic, prognostic, and therapeutic approaches was a major theme
throughout the Symposium. The topics covered at the meeting included: Cancer Genes and Genomes; Cancer
Pathways; Tumor Cell Biology; Cancer Growth & Progression; Innate & Adaptive Immune Responses; and
Enabling Technologies. Several speakers participated in interviews during the course of the Symposium week
and transcripts of those videos and the Dorcas Cummings lecture are included.
"Synopsis" may belong to another edition of this title.
About the Author
"About the title" may belong to another edition of this title.
Revaluation Books
Exeter, United Kingdom
AbeBooks seller since January 6, 2003
Shipping rates from United Kingdom to U.S.A.
| Item | 7 to 14 business days | 2 to 3 business days |
|---|---|---|
| First item | US$ 20.27 | US$ 33.79 |
Payment methods
Seller's business information
Edward Bowditch Ltd
Exstowe, Exton
Exeter, United Kingdom EX3 0PP
Terms of sale
Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch
Shipping terms
Orders usually dispatched within two working days. Please note that at this time all domestic United Kingdom orders are sent by trackable UPS courier, we choose not to offer a lower cost alternative.